Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Albuterol sulfate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Asthma
Interventions: Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more

Conditions: Asthma
Interventions: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 47 more

Conditions: Spinal Cord Injury, Respiratory Muscle Weakness
Interventions: Oral Albuterol Extended Release, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Asthma
Interventions: GSK573719 Active treatment or Placebo, GSK573719 (Sub-group cohort), Salbutamol/Albuterol; Drug · Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Newport Beach, California • Sunset, Louisiana • Bethesda, Maryland + 9 more

Conditions: Pompe Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Exercise Induced Bronchospasm
Interventions: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler; Combination Product
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 3 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Inhaled Treprostinil; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 40 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Asthma
Interventions: fluticasone propionate, fluticasone propionate/salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Huntington Beach, California • Long Beach, California • Riverside, California + 16 more

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrronium bromide, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • Fairhope, Alabama • Glendale, Arizona + 30 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more

Conditions: Asthma
Interventions: Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 19
States / cities: Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide, Fluticasone Propionate/Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more

Conditions: Cystic Fibrosis, Healthy
Interventions: Albuterol, Placebo saline; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 15 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more

Conditions: Asthma
Interventions: Budesonide, albuterol, Ipratropium bromide, Prednisone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: East Meadow, New York • Queens, New York • The Bronx, New York

Conditions: Asthma
Interventions: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 69
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 13
States / cities: Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more

Search by objective public record fields.

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Albuterol to Improve Respiratory Strength in SCI

A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)